Coadagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever has raised $20 million in a new round of financing. The company’s new investment round was led by Adjuvant Capital with additional participation from Euclidean Capital and Topspin Partners . Codagenix will use the funds […]...